Compare ESPR & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | REFI |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.5M | 255.6M |
| IPO Year | 2013 | 2021 |
| Metric | ESPR | REFI |
|---|---|---|
| Price | $3.71 | $13.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $6.86 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 6.5M | 103.0K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 15.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | ★ $303,802,000.00 | $54,287,847.00 |
| Revenue This Year | $25.45 | $13.78 |
| Revenue Next Year | N/A | $4.07 |
| P/E Ratio | ★ N/A | $7.95 |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $0.69 | $11.85 |
| 52 Week High | $4.13 | $16.29 |
| Indicator | ESPR | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 54.99 |
| Support Level | $3.72 | $12.66 |
| Resistance Level | $4.13 | $13.49 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 23.15 | 60.99 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.